This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
TG Therapeutics, Inc. [TGTX], an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs, will visit the NASDAQ MarketSite in Times Square.
In honor of the occasion,
Michael Weiss Executive Chairman & Interim CEO will ring the Closing Bell.
NASDAQ MarketSite – 4 Times Square – 43
rd & Broadway – Broadcast Studio
Thursday, July 11, 2013 – 3:45 p.m. to 4:00 p.m. ET
Contact: Jenna Bosco (212) 554-4484
firstname.lastname@example.orgNASDAQ MarketSite: Christine Barna (646) 441-5310
Christine.Barna@nasdaqomx.comFeed Information: Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For news tweets, please visit our Twitter page at:
A live webcast of the NASDAQ Closing Bell will be available at:
To obtain a hi-resolution photograph of the Market Close, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About TG Therapeutics, Inc. [TGTX]:
TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. TG Therapeutics is headquartered in New York City.